Navigation Links
The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer
Date:7/23/2008

first six weeks of therapy and treated as needed. Bleeding with a fatal outcome from any site was reported in 2.4% for Nexavar and 4% in placebo. The incidence of treatment-emergent cardiac ischemia/infarction was 2.7% for Nexavar vs. 1.3% for placebo. Most common adverse events reported with Nexavar in patients with unresectable HCC were diarrhea, fatigue, abdominal pain, weight loss, anorexia, nausea and hand-foot skin reaction. Grade 3/4 adverse events were 45% for Nexavar vs. 32% for placebo. Women of child-bearing potential should be advised to avoid becoming pregnant and advised against breast-feeding. In cases of any severe or persistent side effects, temporary treatment interruption, dose modification or permanent discontinuation should be considered.

For information about Nexavar including U.S. Nexavar prescribing information, visit http://www.nexavar.com or call 1.866.NEXAVAR (1.866.639.2827).

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar(R) (sorafenib) tablets, a small molecule drug. For more information about Onyx, visit the company's website at: http://www.onyx-pharm.com.

About Bayer HealthCare Pharmaceuticals Inc.

Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals unit of Bayer HealthCare LLC, a division of Bayer AG. One of the world's leading, innovative companies in the healthcare and medical products industry, Bayer HealthCare combines the global activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. In the U.S., Bayer HealthCare Pharmaceuticals comprises the following business units: Women's Healthcare, Diagnostic Imaging, Specialized Therapeu
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals; Onyx Pharmaceuticals,Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxters Cell-Based Pandemic, Avian Flu Vaccine
2. New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study
3. Berkery Noyes Represented The Thomson Corporation in the Sale of CenterWatch and New England Institutional Review Board to Jobson Medical Information
4. New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer
5. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
6. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
7. Vaccine Study in New England Journal of Medicine Wrong in Concluding Mercury Exposures are Harmless, States SafeMinds
8. Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine
9. Bioimpedance Spectroscopy is More Accurate and Reliable Than Other Methods of Subclinical Assessment of Lymphedema in Breast Cancer Patients, According to Paper Published in Journal of Clinical Oncology
10. Groundbreaking American Journal of Play from Strong National Museum of Play(R) Premiers July 2008
11. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)...   BioClinica®, Inc ., a specialty clinical ... it has acquired a leading global patient recruitment ...  The acquisition includes affiliates MediciGlobal , Ltd. ... a lost-to-follow-up patient locate service ( L2FU®) ... BioClinica will offer pharmaceutical companies comprehensive ...
(Date:7/6/2015)... Hologic, Inc. (NASDAQ: HOLX ) announced ... results for the third quarter of fiscal 2015 on ... conjunction with the release, management will host a conference ... Interested participants may listen to the call by ... ) or 719-325-4804 (for international callers) and referencing access ...
(Date:7/6/2015)... FARMINGTON, Conn. , July 6, 2015 ... biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for ... need and commercial potential, today announced that it ... E warrants to purchase 21,917,808 shares of its ... 2,191,781 shares of its common stock.  Certain funds ...
Breaking Medicine Technology:BioClinica Acquires MediciGroup 2BioClinica Acquires MediciGroup 3Hologic to Announce Financial Results for the Third Quarter of Fiscal 2015 on Wednesday, July 29, 2015 2Palatin Technologies Completes $30 Million Financing 2Palatin Technologies Completes $30 Million Financing 3Palatin Technologies Completes $30 Million Financing 4Palatin Technologies Completes $30 Million Financing 5
(Date:7/6/2015)... ... July 06, 2015 , ... ... radiology services and ADVOCATE is leading the transition. ADVOCATE, the only 100% radiology, ... their Top 10 Tips for ICD-10. The ten tips are timely and relevant ...
(Date:7/6/2015)... ... 2015 , ... Cancer Hope Network (CHN) has relaunched their ... to chat with the CHN patient services team and connect with a Support ... often the most traumatic experience of a person’s life,” said CHN Executive Director, ...
(Date:7/6/2015)... ... July 06, 2015 , ... With a ... once again teamed up with Family Emergency Shelter Coalition (FESCO) and announced a ... FESCO was created especially to provide emergency services and support for homeless families, ...
(Date:7/6/2015)... ... July 06, 2015 , ... With a new community program ... Livonia Save Our Youth and announced a new charity campaign to raise funds in ... alcohol and drug abuse. Livonia Save Our Youth is a coalition created especially to ...
(Date:7/6/2015)... ... ... Dr. Lawrence Green is now offering the newly FDA-approved Kybella injectable to ... method to dissolve fat cells and is the first of its kind to be ... commonly known as a double chin. Dr. Green participated in clinical trials for Kybella ...
Breaking Medicine News(10 mins):Health News:ADVOCATE Takes the Lead to Ensure ICD-10 Success: “Top 10 Tips for ICD-10” 2Health News:Cancer Hope Network Launches Upgraded Website to Support Cancer Patients, Caregivers 2Health News:Carlson & Associates Insurance Agency and Nonprofit Family Emergency Shelter Coalition (FESCO) Initiate New Charity Campaign in Alameda County, CA to Provide for Homeless 2Health News:Carlson & Associates Insurance Agency and Nonprofit Family Emergency Shelter Coalition (FESCO) Initiate New Charity Campaign in Alameda County, CA to Provide for Homeless 3Health News:Bowker Insurance Group and Nonprofit Livonia Save Our Youth Initiate New Charity Campaign in Livonia, MI to Provide for The Health and Safety of The Communities’ Youth 2Health News:Bowker Insurance Group and Nonprofit Livonia Save Our Youth Initiate New Charity Campaign in Livonia, MI to Provide for The Health and Safety of The Communities’ Youth 3Health News:Rockville, MD Practice Now Offering New FDA-Approved Non-Surgical Double Chin Treatment 2
... July 13, 2010 The decision regarding treatment following ... (DCIS) has long been an area of discussion and ... rates for DCIS remain low, the risk of local ... surgery include radiation therapy and hormone treatment. While ...
... Science Associates, the company that manages the U.S. ... Engineering Technologies, Inc. (BioSET) of Rockville, Maryland, have ... second-generation technology for designing synthetic peptides that are ... are designed to communicate growth signals to cells ...
... HealthDay Reporter , TUESDAY, July 13 (HealthDay News) -- ... decade ago that the blockbuster diabetes drug caused an increased ... to a report published Tuesday in The New York ... its competitor, Actos, the drug company, then known as SmithKline ...
... ARBOR, Mich.---Dostoyevsky and Tolstoy portrayed Russians as a brooding, ... to focus on dark feelings and memories more than ... finds that even though Russians tend to brood, they ... as a result. "Among Westerners, focusing on one,s ...
... health threats ranging from swine flu to bioterrorism to ... vast potential to protect the public. In a paper ... in Emerging Health Threats Journal , public health ... surveillance, detailing innovations on the horizon that may facilitate ...
... Children and young adults with Tourette syndrome can gain control ... suggests. But a specialist in the condition said the ... works. In the study, reported in the July/August ... , researchers used a video to teach 33 people aged ...
Cached Medicine News:Health News:Prediction tool helps estimate local recurrence in patients with noninvasive breast cancer 2Health News:Prediction tool helps estimate local recurrence in patients with noninvasive breast cancer 3Health News:Brookhaven Lab and BioSET Inc. patent improved growth factor technology 2Health News:Avandia Heart Risks Buried by Drug Company: Report 2Health News:Avandia Heart Risks Buried by Drug Company: Report 3Health News:Brooding Russians: Less distressed than Americans 2Health News:Researchers envision better disease surveillance to improve public health 2Health News:Can Self-Hypnosis Help Tourette Patients Control Tics? 2
Intermittent catheter...
... Focus from Thermo Labsystems was designed specifically ... Advanced features such as the new fast ... on microvolumes help to define this as ... The new interchangeable handle plate offers a ...
Disease diagnosis and treatment reference sourced from Griffith's 5-Minute Clinical Consult. Save time diagnosing and treating more than 1,200 diseases and conditions....
... Flexible Band is a flexible partial ... alternative for surgeons who desire posterior ... Tailor® Annuloplasty Ring, which is designed ... rings, but like the option of ...
Medicine Products: